Show simple item record

dc.contributor.advisorKayed, Rakez
dc.creatorKantara, Carla
dc.date.accessioned2016-11-14T15:20:10Z
dc.date.available2016-11-14T15:20:10Z
dc.date.created2012-05
dc.date.submittedMay 2012
dc.identifier.urihttp://hdl.handle.net/2152.3/659
dc.identifier.urihttp://hdl.handle.net/2152.3/810
dc.description.abstractColorectal-cancer is a leading cause of cancer deaths in United States. Accumulating evidence suggests that elevated progastrins (PG) increase the risk of colon carcinogenesis, however mechnaims involved remain ill-defined. Recently, cell-surface AnnexinA2 (CS-ANXA2) was discovered as a non-conventional receptor for progastrin. Therefore, the first goal was to examine whether ANXA2 expression is required to mediate proliferative/anti-apoptotic effects of progastrin on target cells. The studies in chapter 2, conclude that ANXA2 mediates growth effects of PG on target cells (including colonic-epithelial-cells), in vitro and in vivo, associated with up-regulation of stem/progenitor cell markers. Surprisingly, overexpression of autocrine PG in HEK-293 cells, imparted tumorigenic/metastatic potential to the cells (chapter 3). Based on these data, the second goal was to investigate the phenotypic differences between non-transformed and transformed stem cell using non-tumorigenic (HEK-C) and tumorigenic (HEK-mGAS) isogenic cells. The studies in chapter 3, conclude that transformed stem cells, unlike normal stem cells, co-express CS-ANXA2 with stem-cell-markers DCAMKL-1/CD44. Interestingly, CS-ANXA2 dictates morphology/growth characteristics of spheroidal growths, in vitro. The third goal was to identify cancer stem cell (CSC) marker(s), for developing targeted therapies against colon cancers. Since both DCAMKL-1/LGR5 have been reported as colonic CSC markers, the possible phenotypic/proliferative differences between DCAMKL-1+ve and LGR5+ve human colon CSCs was examined. Results in chapter 4 suggest that DCAMKL-1+ve cells are significantly more proliferative than either DCAMKL-1-ve or LGR5+ve stem cells. Thus targeting DCAMKL-1+ve cells may be more effective in treating/eradicating colon-cancers; this possibility was examined as part of my fourth goal. Although several therapies are currently available for treating cancers, recurrence remains a challenge. It is believed that CSCs are resistant to radiation and chemotherapeutic treatments, and are the likely cause of cancer relapse. It is therefore important to develop novel therapies which are relatively non-toxic and specifically target CSCs. Therefore the fourth goal was to examine the inhibitory efficacy of non-toxic dietary agent (Curcumin) ± RNAi against DCAMKL-1. The results in chapter 5 suggest that combination of curcumin+siRNA-DCAMKL-1 effectively attenuates growth of colon-cancer-cells in vitro and in vivo, by synergistically augmenting autophagic/apoptotic cell-death mechanisms. It is hypothesized that the combinatorial treatment will significantly reduce the risk of relapse.
dc.format.mimetypeapplication/pdf
dc.subjectStem Cells
dc.subjectColon Cancer
dc.subjectDCAMKL-1, LGR5, Curcumin, AnnexinA2.
dc.titleGrowth Factors Up-Regulate Epithelial Stem Cells: Treatment Strategies for Colorectal Cancers
dc.typeThesis
dc.date.updated2016-11-14T15:20:10Z
dc.type.materialtext
thesis.degree.nameCell Biology (Doctoral)
thesis.degree.levelDoctoral
thesis.degree.disciplineCancer Research
thesis.degree.grantorThe University of Texas Medical Branch at Galveston
thesis.degree.departmentCell Biology
dc.contributor.committeeMemberSingh, Pomila
dc.contributor.committeeMemberUllrich, Robert
dc.contributor.committeeMemberCarney, Darrell
dc.contributor.committeeMemberUmar, Shahid


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record